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Summary of findings {#CD002150-sec1-0001}
===================

Summary of findings for the main comparisonDoxycycline compared to tetracycline for treating scrub typhus**Doxycycline compared to tetracycline for treating scrub typhusPatient or population:** adults with scrub typhus\
**Settings:** hospitals in endemic areas\
**Intervention:** doxycycline 200 mg single oral dose ([@CD002150-bbs2-0001]), doxycycline oral 100 mg 12‐hourly for 3 days ([@CD002150-bbs2-0006])\
**Comparison:** tetracycline 500 mg 6‐hourly for 7 days ([@CD002150-bbs2-0001]), tetracycline oral 500 mg 12‐hourly for 7 days ([@CD002150-bbs2-0006])**OutcomesAnticipated absolute effects\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with tetracyclineRisk with doxycycline**Treatment failure0 events in 50 participants4 events in 66 participantsRR 6.85\
(0.38 to 124.38)116 (1 RCT)⊕⊝⊝⊝ VERY LOW^a,b^\
Due to risk of bias and imprecisionWe are uncertain whether doxycycline compared to tetracycline affects treatment failure, as the certainty of the evidence is very low.Resolution of fever within 48 hours792 per 1000902 per 1000\
(713 to 1000)RR 1.14\
(0.90 to 1.44)55 (1 RCT)⊕⊕⊝⊝ LOW^c,d^\
Due to risk of bias and imprecisionDoxycycline compared to tetracycline may make little or no difference in the proportions of patients with resolution of fever within 48 hours.Resolution of fever within 5 daysNot reportedNeither of the studies looked at resolution of fever within 5 days.Time to defervescenceMean 37 hours, SD 26.6 hoursMean 34 hours, SD 26.5 hours‐116 (1 RCT)⊕⊕⊝⊝ LOW^a,e^\
Due to risk of bias and imprecisionDoxycycline compared to tetracycline may make little or no difference in time to defervescence.Serious adverse eventsNot formally reported\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; SD: standard deviation.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate **Very low certainty:** we are very uncertain about the estimate[^2]

Summary of findings 2Macrolides compared to doxycycline for treating scrub typhus**Macrolides compared to doxycycline for treating scrub typhusPatient or population:** adults and adolescents with scrub typhus\
**Settings:** hospitals in endemic areas\
**Intervention:** doxycycline 200 mg per day for 7 days ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0005]); doxycycline 200 mg per day for 5 days ([@CD002150-bbs2-0004]) **Comparison:** azithromycin 500 mg single oral dose ([@CD002150-bbs2-0003]); telithromycin 800 mg daily for 5 days ([@CD002150-bbs2-0004]); azithromycin 1 g daily for 3 days, followed by 500 mg daily for 2 days ([@CD002150-bbs2-0005])**OutcomesAnticipated absolute effects\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with doxycyclineRisk with macrolides**Treatment failureAssumed risk:\
19 per 1000^a^51 per 1000 (2 to 1000)RR 2.71 (0.12 to 63.84)242 (3 RCTs)⊕⊝⊝⊝ VERY LOW^b,c^\
Due to risk of bias and imprecisionWe are uncertain whether macrolides compared to doxycycline affect treatment failure, as the certainty of the evidence is very low.Resolution of fever within 48 hours671 per 1000544 per 1000 (215 to 1000)RR 0.81 (0.32 to 2.03)150 (2 RCTs)⊕⊝⊝⊝ VERY LOW^b,d^\
Due to risk of bias, imprecision, and inconsistencyWe are uncertain whether macrolides compared to doxycycline affects the proportion of patients with resolution of fever within 48 hours.Resolution of fever within 5 days956 per 10001000 per 1000 (946 to 1000)RR 1.05 (0.99 to 1.10)185 (2 RCTs)⊕⊕⊝⊝ LOW^b,e^\
Due to risk of bias and inconsistencyMacrolides compared to doxycycline may make little or no difference in the proportion of patients with resolution of fever within 5 days.Time to defervescenceEach included study detected no significant difference between groups.242 (3 RCTs)⊕⊝⊝⊝ VERY LOW^b,d^\
Due to risk of bias and inconsistencyWe are uncertain whether macrolides compared to doxycycline affect time to defervescence, as the certainty of the evidence is very low.Serious adverse eventsNo included trial reported serious adverse events.242 (3 RCTs)⊕⊝⊝⊝ VERY LOW^b,c^\
Due to risk of bias and imprecisionWe are uncertain whether macrolides compared to doxycycline affects serious adverse events, as the certainty of the evidence is very low.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect[^3]

Summary of findings 3Rifampicin compared to doxycycline for treating scrub typhus**Rifampicin compared to doxycycline for treating scrub typhusPatient or population:** adults with scrub typhus\
**Settings:** hospitals in endemic areas\
**Intervention:** rifampicin\
**Comparison:** doxycycline**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskdoxycyclinerifampicin**Treatment failureThe included reported no treatment failures.‐78 (1 RCT)⊕⊝⊝⊝ VERY LOW^a,b^\
Due to risk of bias and imprecisionWe are uncertain whether rifampicin compared to doxycycline affects treatment failure, as the certainty of the evidence is very low.Resolution of fever within 48 hours464 per 1000780 per 1000 (510 to 1000)RR 1.68\
(1.10 to 2.57)78 (1 RCT)⊕⊝⊝⊝ VERY LOW^a,c^\
Due to risk of bias and imprecisionWe are uncertain whether rifampicin compared to doxycycline affects the proportion of patients with resolution of fever within 48 hours, as the certainty of the evidence is very low.Resolution of fever within 5 daysNot reportedThe study did not look at resolution of fever within 5 days.Time to defervescenceStudy authors report that time to defervescence was less with rifampicin.‐78 (1 RCT)⊕⊝⊝⊝ VERY LOW^a,c^\
Due to risk of bias and imprecisionWe are uncertain whether rifampicin compared to doxycycline affects time to defervescence, as the certainty of the evidence is very low.Serious adverse eventsNot formally reported\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate **Very low certainty:** we are very uncertain about the estimate[^4]

Background {#CD002150-sec1-0002}
==========

Description of the condition {#CD002150-sec2-0001}
----------------------------

Scrub typhus is an important cause of acute fever in Asia. It is caused by *Orientia tsutsugamushi* (formerly *Rickettsia tsutsugamushi),* an obligate intracellular bacterium in the order Rickettsia. This bacterium is transmitted in the bite of larvae of the *Leptotrombidium* mite, commonly called chiggers, which form the reservoir. Clinical features are non‐specific and include fever, headache, and myalgia ([@CD002150-bbs2-0043]). An eschar, an ulcerated lesion with a black crust, may develop at the site of the bite. The frequency of eschar formation varies across populations from 7% to 80%. Scrub typhus may lead to pneumonia, shock, meningoencephalitis, renal failure, or myocarditis ([@CD002150-bbs2-0030]). Disease severity appears to be related to the virulence of the *O tsutsugamushi* strain, patient age, patient genetic factors, and previous infections, but literature regarding prognostic factors is limited ([@CD002150-bbs2-0035]). For untreated scrub typhus, median mortality is 6% (range 0 to 70%) ([@CD002150-bbs2-0040]). With treatment, median mortality is 1.4% (range 0 to 33.3%) ([@CD002150-bbs2-0026]).

As *O tsutsugamushi* is intracellular, it cannot be isolated via standard bacterial culture but instead requires cell culture. Therefore, the main modalities for diagnosis of scrub typhus are nucleic acid amplification tests (for example, polymerase chain reaction (PCR)) and serology (including immunofluorescence assays (IFAs), rapid diagnostic tests (RDTs), and enzyme‐linked immunosorbent assay (ELISA)). The historical mainstay of diagnosis has been indirect immunofluorescence assay, but this is limited by subjectivity and a requirement for paired acute and convalescent sera. Increasingly, ELISA tests are replacing IFAs, as they are more sensitive, specific, and reproducible. Real‐time PCR on blood or eschar biopsy is helpful in diagnosing early‐stage infection ([@CD002150-bbs2-0034]). In some resource‐limited settings, the only serological test available is the Weil‐Felix test, a non‐specific antibody agglutination test that cannot distinguish *O tsutsugamushi* from other Rickettsial infections ([@CD002150-bbs2-0033]).

Scrub typhus is endemic to Asia‐Pacific. Most cases occur in a region traditionally known as the 'tsutsugamushi triangle', which extends from Japan to India, and to Northern Australia. Incidence varies across the region, ranging from 1.2 to 17.7 per 100,000 per year. Seroprevalence similarly varies, ranging from 9.3% to 27.9% ([@CD002150-bbs2-0026]). In the Mekong region, scrub typhus represents the second most common cause of non‐malarial febrile illness after dengue ([@CD002150-bbs2-0025]). Infection classically occurs when humans encroach upon \'mite islands\' ‐ discrete areas where infected chiggers are found. For this reason, cases often occur in association with land clearing, logging, or military operations; in rice fields; and during outdoor travel activities ([@CD002150-bbs2-0043]).

Description of the intervention {#CD002150-sec2-0002}
-------------------------------

Antibiotics currently recommended to treat scrub typhus include the following ([@CD002150-bbs2-0027]).

Tetracyclines: doxycycline 100 mg twice per day for one week. In clinical practice, this is favoured over tetracycline owing to convenience of the dosing schedule.Chloramphenicol.Macrolides: azithromycin.Rifampicin.

A previous version of this review also identified fluoroquinolones as a possible alternative treatment ([@CD002150-bbs2-0045]).

How the intervention might work {#CD002150-sec2-0003}
-------------------------------

Doxycycline historically has been the mainstay of treatment across the rickettsial diseases, including scrub typhus. Given the difficulties associated with cell culture, there is a relative paucity of in vitro susceptibility data needed to provide a theoretical basis for its use. Chloramphenicol is the traditional second‐line treatment and was one of the first drugs found to be effective ([@CD002150-bbs2-0038]).

Several reports have indicated suspected doxycycline resistance inferred by treatment failures in cohort studies such as [@CD002150-bbs2-0041], or due to acquisition of scrub typhus during doxycycline malaria prophylaxis ([@CD002150-bbs2-0028]). However, few studies have correlated clinical evidence suggesting drug resistance with in vitro data, possibly because of the difficulty involved in culturing *O tsutsugamushi*. [@CD002150-bbs2-0042] studied 19 patients with scrub typhus and through mouse fibroblast cell culture identified one isolate as doxycycline‐resistant and another isolate as showing partial resistance; these findings correlated with attenuated therapeutic response. Whole‐genome sequencing has indicated the presence of putative resistance genes, but evaluating their potential to mediate resistance is challenging ([@CD002150-bbs2-0032]). Overall, we found uncertain evidence to support the existence or clinical significance of doxycycline resistance in *O tsutsugamushi,* and this remains a public health concern.

Fluoroquinolones such as ciprofloxacin have been used; however, one in vitro study indicates that *O tsutsugamushi* may be intrinsically resistant to these antibiotics ([@CD002150-bbs2-0039]).

Why it is important to do this review {#CD002150-sec2-0004}
-------------------------------------

This is an update of a Cochrane Review first published in 2000 ([@CD002150-bbs2-0046]), and later updated ([@CD002150-bbs2-0045]), which identified seven small trials and presented several limited conclusions.

The review authors concluded that rifampicin seemed to be more effective than doxycycline in areas where scrub typhus responds poorly to standard drugs; they based these conclusions on data from one study ([@CD002150-bbs2-0007]). A recent non‐Cochrane systematic review performed an analysis of the same study and reached a different conclusion ([@CD002150-bbs2-0044]), cautioning against interpreting the results in favour of rifampicin. The disagreement marked an important reason to update this review. Since the last update in 2002, the review process has become more sophisticated. This updated review is improved by GRADE methods and \'Summary of findings\' tables, which enable more conclusions and provide clear indications to the reader regarding the certainty of evidence presented. [@CD002150-bbs2-0044] did not use GRADE methods.

Scrub typhus remains an important cause of morbidity in endemic areas, and choice of antibiotic remains a topical clinical question.

Objectives {#CD002150-sec1-0003}
==========

To assess and compare the effects of different antibiotic regimens for treatment of scrub typhus.

Methods {#CD002150-sec1-0004}
=======

Criteria for considering studies for this review {#CD002150-sec2-0005}
------------------------------------------------

### Types of studies {#CD002150-sec3-0001}

We searched for all relevant randomized controlled trials (RCTs) and quasi‐RCTs. We define quasi‐RCTs as those using an allocation method that is not truly random (for example, based on date of birth).

### Types of participants {#CD002150-sec3-0002}

Trials had to include people with a diagnosis of scrub typhus based on clinical symptoms and compatible laboratory tests, including the following.

Serology (IFA, ELISA, RDT).Nucleic acid amplification (PCR).Isolation (cell culture).

Given the poor specificity of the Weil‐Felix test, we excluded studies that used this as the sole measure to confirm the diagnosis.

### Types of interventions {#CD002150-sec3-0003}

#### Interventions {#CD002150-sec4-0001}

Anti‐rickettsial antibiotics, irrespective of route of administration, dose, dose frequency, or course duration.

#### Controls {#CD002150-sec4-0002}

Other anti‐rickettsial antibiotics. We excluded studies comparing interventions versus placebo or no drug as it is clear antibiotics are effective. We planned to include trials that provided additional interventions to all treatment arms, but we did not encounter such trials.

### Types of outcome measures {#CD002150-sec3-0004}

#### Primary outcomes {#CD002150-sec4-0003}

Treatment failure, defined as persistence of symptoms at the end of the treatment course.Resolution of fever within 48 hours.

#### Secondary outcomes {#CD002150-sec4-0004}

Resolution of fever within five days.Time to defervescenceDefined as the time interval between administration of the first dose of antibiotic and the first time at which temperature was less than 37.5°C and was thereafter maintained for \> 48 hours.Serious adverse events.Frequency and types of reported adverse events.

Search methods for identification of studies {#CD002150-sec2-0006}
--------------------------------------------

We performed a comprehensive search to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and ongoing) up to 8 January 2018.

### Electronic searches {#CD002150-sec3-0005}

We searched the following databases using the search terms and strategy detailed in [Table 10](#CD002150-tbl-0010){ref-type="table"}.Table 1Detailed search strategy**Search setCIDG SR^a^CENTRALMEDLINE^b^Embase^b^LILACS^b^**1Scrub typhusSCRUB TYPHUSSCRUB TYPHUSSCRUB TYPHUSScrub typhus2*Rickettsia tsutsugamushi*Scrub typhus \[ti, ab\]Scrub typhus \[ti, ab\]Scrub typhus \[ti, ab\]*Rickettsia tsutsugamushi*3*Orientia tsutsugamushiOrientia tsutsugamushi* \[ti, ab\]*Orientia tsutsugamushi* \[ti, ab\]*Orientia tsutsugamushi* \[ti, ab\]*Orientia tsutsugamushi*41 or 2 or 3*Rickettsia tsutsugamushi* \[ti, ab\]*Rickettsia tsutsugamushi* \[ti, ab\]*Rickettsia tsutsugamushi* \[ti, ab\]1 or 2 or 35¬*ORIENTIA TSUTSUGAMUSHIORIENTIA TSUTSUGAMUSHIORIENTIA TSUTSUGAMUSHI*¬6¬1 or 2 or 3 or 4 or 51 or 2 or 3 or 4 or 51 or 2 or 3 or 4 or 5¬7¬¬Limit 6 to humansLimit 6 to humans¬[^5]

Cochrane Infectious Diseases Group Specialized Register.Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (2018, Issue 1).MEDLINE (1966 to January 2018).Embase (1980 to January 2018).Latin American Caribbean Health Sciences Literature (LILACS) (1982 to January 2018).

We searched the *meta*Register of Controlled Trials (*m*RCT) using \'\'scrub typhus\'\' OR \'\'orientia tsutsugamushi\'\', \"antibiotics\" OR \'\'antimicrobial therapy\'\' as search terms. The search strategy remains unchanged since the previous version of the protocol was prepared.

### Searching other resources {#CD002150-sec3-0006}

#### Reference lists {#CD002150-sec4-0005}

To identify additional published, unpublished, and ongoing studies, we checked the reference lists of all studies identified by the above methods.

Data collection and analysis {#CD002150-sec2-0007}
----------------------------

### Selection of studies {#CD002150-sec3-0007}

For this update, two review authors (IES and IW) independently screened search results to identify potentially relevant trials and obtained the full‐text reports of these trials. For English language studies, IES and IW then used a standard eligibility form to assess newly identified studies and to re‐assess previously included studies against inclusion and exclusion criteria. For Chinese language studies, IW and QL followed the same process. We resolved disagreements by discussion with a third review author (PH). We documented reasons for excluding trials in the [Characteristics of excluded studies](#CD002150-sec2-0019){ref-type="sec"} table. We scrutinized each trial report to ensure that we did not include multiple publications from the same trial.

### Data extraction and management {#CD002150-sec3-0008}

Three review authors (IES, QL, and IW) independently extracted data onto a data extraction form (modified from previous versions of this review). We extracted information on study design, setting, population, diagnostic criteria, antibiotic regimen (dose, route, duration, timing, and frequency), total numbers randomized, number of participants in each group, numbers lost to follow‐up, duration of follow‐up, dates of the study, funding source, and withdrawals from each group. We encountered no disagreements.

For dichotomous data, we extracted the number of participants who experienced the event of interest and the number of participants randomized and analysed in each group.

For continuous outcomes, we extracted mean values, standard deviations, and number of participants in each group for whom the outcome was assessed. When medians were reported, we extracted ranges or interquartile ranges. When data were incomplete, we contacted trial authors to request additional data.

### Assessment of risk of bias in included studies {#CD002150-sec3-0009}

Three review authors (IES, QL, and IW) independently assessed potential biases of included studies using a prepared form and the Cochrane 'Risk of bias' tool ([@CD002150-bbs2-0031]). For each domain, we described what trial authors reported and made a subjective judgement for each domain as having 'high, low, or unclear' risk of bias. We resolved discrepancies by discussion and reached agreement. We included all assessments in a \'Risk of bias\' graph and a \'Risk of bias\' summary figure. We provided in the [Results](#CD002150-sec1-0005){ref-type="sec"} section a narrative description of our risk of bias conclusions for each domain of all included studies.

We assessed the following domains for each study: sequence generation, allocation concealment, blinding or masking, incomplete outcome data, selective outcome reporting, and other sources of bias.

#### Sequence generation {#CD002150-sec4-0006}

We described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We considered trials as having low risk of bias if the investigator described a random component of sequence generation (for example, a random number table, a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing lots, minimization); high risk of bias if sequence generation was non‐random (for example, sequence generated by odd or even date of birth, some rule based on date (or day) of admission, some rule based on hospital or clinic record number); or unclear risk of bias if the randomization process was not clearly described.

#### Allocation concealment {#CD002150-sec4-0007}

We assessed whether participants and investigators enrolling participants could foresee assignment. We judged this domain as having low risk of bias if the investigator used central allocation (including telephone‐based, web‐based, and pharmacy‐controlled randomization), sequentially numbered drug containers of identical appearance, or sequentially numbered opaque, sealed envelopes to conceal allocation; high risk of bias if the allocation process was not concealed (for example, open randomization, unsealed or non‐opaque envelopes); or unclear risk of bias if study authors did not describe the process of concealing allocation sufficiently to permit a judgement.

#### Blinding of participants or personnel {#CD002150-sec4-0008}

We described whether blinding was done and who was blinded. We regarded a trial as having low risk of performance bias if blinding was done; high risk of bias if blinding was not done and this was likely to affect the results; or unclear risk of bias if study authors did not clearly describe blinding.

#### Blinding of outcome assessment {#CD002150-sec4-0009}

We described knowledge of allocated interventions by outcome assessors. All primary and secondary outcomes in our review are subjective. So, we judged trials as having low risk of detection bias if blinding of outcome assessment was ensured and it was unlikely that the blinding could have been broken; high risk of detection bias if no blinding of outcome assessment was performed; or unclear risk of detection bias if study authors did not adequately describe this domain to allow a judgement of 'low risk' or 'high risk'.

#### Incomplete outcome data {#CD002150-sec4-0010}

We assessed the proportions of missing outcome data between different groups. We judged trials as having a low level of attrition bias if the proportion of participants lost to follow‐up was \< 10%, or if missing outcome data were balanced in numbers across intervention groups, with similar reasons provided for missing data across groups. We regarded trials as having high risk of attrition bias if the proportion of participants lost to follow‐up was \> 10%, or if reasons for missing outcome data were likely to be related to true outcomes, with imbalance in numbers or reasons for missing data across intervention groups. We judged trials as having unclear risk of attrition bias if study authors did not adequately describe this domain to permit a judgement of 'low risk' or 'high risk'.

#### Selective outcome reporting {#CD002150-sec4-0011}

We determined that if published reports included all expected outcomes, including those prespecified in the [Methods](#CD002150-sec1-0004){ref-type="sec"} section, then those trials had low risk of bias. We considered trials to have high risk of bias if not all of the study's prespecified primary outcomes were reported; if one or more primary outcomes were reported through measurement or analysis methods that were not prespecified; or if one or more reported primary outcomes were not prespecified.

#### Other sources of bias {#CD002150-sec4-0012}

We assessed other potential sources of bias related to the specific study design used, baseline imbalance, and deviation from the trial protocol.

### Measures of treatment effect {#CD002150-sec3-0010}

We calculated the risk ratio (RR) for dichotomous outcomes. We presented all measures with corresponding 95% confidence intervals (CIs). When we assessed the data, we regarded time to defervescence as a time‐to‐event outcome, as we were not certain whether all participants experienced this outcome. We therefore decided it was inappropriate to analyse time to defervescence using methods for continuous outcomes. We were unable to extract the log hazard ratio and its standard error from Cox proportional hazards models; therefore we did not combine this outcome in the meta‐analysis but instead presented a narrative analysis.

### Unit of analysis issues {#CD002150-sec3-0011}

We did not encounter unit of analysis issues.

### Dealing with missing data {#CD002150-sec3-0012}

We extracted data to allow an intention‐to‐treat analysis in which all randomized participants were analysed in the groups to which they were originally assigned, outcome data were provided on all participants, and all randomized participants were included in the analysis. For three included studies ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0006]; [@CD002150-bbs2-0007]), we tried to contact the study authors to request missing data. We emailed the corresponding author for one study ([@CD002150-bbs2-0007]), but we did not receive a reply. We did not find email addresses for corresponding authors for two included studies ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0006]). We then conducted a complete‐case analysis and included in the analysis only participants with a recorded outcome.

### Assessment of heterogeneity {#CD002150-sec3-0013}

We visually inspected forest plots that displayed overlapping confidence intervals for two or more studies as an indicator of clinical heterogeneity. We assessed statistical heterogeneity using Chi² and I² tests. We considered a Chi² test P value \< 0.1 and an I² statistic value \> 75% as indicating substantial heterogeneity.

### Assessment of reporting biases {#CD002150-sec3-0014}

We planned to investigate potential publication bias by using a funnel plot if at least 10 studies met the inclusion criteria of the review.

### Data synthesis {#CD002150-sec3-0015}

We analysed the data using Review Manager 5 (RevMan 5) ([@CD002150-bbs2-0036]). We used a fixed‐effect model and Mantel‐Haenszel methods if we noted no heterogeneity. Otherwise, we used a random‐effects model and Mantel‐Haenszel methods for significant heterogeneity.

#### Certainty of the evidence {#CD002150-sec4-0013}

We assessed the certainty of the evidence using the GRADE approach ([@CD002150-bbs2-0037]). We appraised the certainty of evidence in relation to the following criteria.

Study design.Risk of bias.Inconsistency.Indirectness.Imprecision.Other considerations (including publication bias).

We used GRADEpro GDT software to create \'Summary of findings\' tables for comparisons included in the review ([@CD002150-bbs2-0029]). We included our primary outcomes and used these tables to guide our conclusions.

### Subgroup analysis and investigation of heterogeneity {#CD002150-sec3-0016}

We planned to investigate heterogeneity by conducting prespecified subgroup analyses for primary outcomes, according to the following potential sources.

Geographical setting, which may influence antibiotic susceptibility.Date of the study (before or after antibiotic resistance was first reported).Participant age (children versus adults).Dose, frequency, and duration of treatment.

However, the number of included studies for each comparison was not sufficient to permit subgroup analysis.

### Sensitivity analysis {#CD002150-sec3-0017}

We planned to assess the robustness of summary estimates by restricting analysis to studies with low risk of bias, especially in terms of allocation concealment and low incomplete follow‐up (\< 10%), but the number of included studies was not sufficient.

Results {#CD002150-sec1-0005}
=======

Description of studies {#CD002150-sec2-0008}
----------------------

### Results of the search {#CD002150-sec3-0018}

The previous version of this review included seven studies. We re‐screened these according to our eligibility criteria and excluded one previously included study, as those researchers used only the Weil‐Felix test for laboratory diagnosis ([@CD002150-bbs2-0015]).

Through the updated literature search on 8 January 2018, we identified 128 references. We excluded 36 duplicate records and excluded 81 of the remaining 92 references after title and abstract screening. We assessed 12 full‐text articles for eligibility, from which we excluded 10 articles (see [Characteristics of excluded studies](#CD002150-sec2-0019){ref-type="sec"}). One new study ‐ [@CD002150-bbs2-0002] ‐ met the inclusion criteria, in addition to six previously included studies (see [Characteristics of included studies](#CD002150-sec2-0018){ref-type="sec"}), and two new ongoing trials met these criteria (see [Characteristics of ongoing studies](#CD002150-sec2-0020){ref-type="sec"}). In total, seven studies (in seven publications) met the inclusion criteria of this review ([Figure 1](#CD002150-fig-0001){ref-type="fig"}).Figure 1PRISMA flow diagram.

### Included studies {#CD002150-sec3-0019}

Seven studies met our inclusion criteria (see [Characteristics of included studies](#CD002150-sec2-0018){ref-type="sec"}).

Six were RCTs ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]; [@CD002150-bbs2-0007]), and one was a quasi‐RCT ([@CD002150-bbs2-0004]). These studies contributed 548 participants to this review.

All studies took place within hospital settings, located in Korea (three trials), Malaysia (one trial), and Thailand (three trials).

The point at which participants were randomized varied between studies.

One study randomized patients with acute undifferentiated fever ([@CD002150-bbs2-0005]).Four studies randomized patients with clinically suspected scrub typhus ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0006]).Two studies randomized patients after a positive RDT ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0007]).

The number of randomized participants ranged from 57 in [@CD002150-bbs2-0002], to 296 in [@CD002150-bbs2-0005]. Five studies recruited adults only (n = 434); one study recruited people aged 14 and over (n = 57; [@CD002150-bbs2-0005]); and one study recruited children under the age of 15 (n = 57; [@CD002150-bbs2-0002]). All studies recruited males and females.

Four studies confirmed diagnosis using IFA only ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]); one study confirmed diagnosis using IFA, agglutination testing, or isolation ([@CD002150-bbs2-0001]); one study used only screening RDT for laboratory confirmation ([@CD002150-bbs2-0002]); and another study used screening RDT followed by confirmatory indirect immunoperoxidase ([@CD002150-bbs2-0007]).

Two trials compared doxycycline and tetracycline ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0006]); and four trials compared doxycycline versus a macrolide ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]). [@CD002150-bbs2-0002] investigated children and used chloramphenicol in place of doxycycline for children under the age of eight but did not report results for chloramphenicol and doxycycline separately. One trial compared doxycycline alone, rifampicin alone at low and high doses, and doxycycline and rifampicin in combination ([@CD002150-bbs2-0007]).

Included studies reported a variety of outcome measures and used different terminology to incorporate similar categories. With respect to our primary outcomes:

treatment failure: six studies provided data ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]; [@CD002150-bbs2-0007]). Definitions of treatment failure varied according to the persistence of fever and/or symptoms at time points including 48 hours, 72 hours, and after treatment completion; andresolution of fever within 48 hours: two studies provided data ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0007]).

With respect to our secondary outcomes:

resolution of fever within five days: three studies provided data ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]);time to defervescence: six studies provided data ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]; [@CD002150-bbs2-0007]); andadverse events: all studies provided data.

### Excluded studies {#CD002150-sec3-0020}

We excluded 13 studies (see [Characteristics of excluded studies](#CD002150-sec2-0019){ref-type="sec"}) for the following reasons: five studies were retrospective and confirmed laboratory diagnosis via the Weil‐Felix test only; four studies had an unclear study design and confirmed laboratory diagnosis via the Weil‐Felix test only; two studies assessed antibiotics for preventing rather than treating scrub typhus; and two studies confirmed laboratory diagnosis via the Weil‐Felix test only, one of which was included in the previous version of this review ([@CD002150-bbs2-0015]).

Risk of bias in included studies {#CD002150-sec2-0009}
--------------------------------

See [Figure 2](#CD002150-fig-0002){ref-type="fig"} for a summary of the 'Risk of bias\' assessments. Further details are available in the [Characteristics of included studies](#CD002150-sec2-0018){ref-type="sec"} table.Figure 2Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD002150-sec3-0021}

We judged four studies to have low risk of selection bias because they adequately described generation of allocation sequences ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]). We judged one study as having high risk of selection bias because researchers randomized participants according to the last digit of a registration number ([@CD002150-bbs2-0004]). We judged two studies to have unclear risk of selection bias as study authors did not provide sufficient information ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0007]).

Allocation concealment was unclear in all trials except one, which used an opaque and numbered envelope for allocation concealment ([@CD002150-bbs2-0005]).

### Blinding {#CD002150-sec3-0022}

Five studies were open‐label and provided inadequate blinding of participants and providers. We judged these studies as having high risk of performance and detection bias ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]). Description of blinding was unclear in [@CD002150-bbs2-0001] and [@CD002150-bbs2-0007].

### Incomplete outcome data {#CD002150-sec3-0023}

We assessed five trials to be at low risk of attrition bias ([@CD002150-bbs2-0002]; [@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]; [@CD002150-bbs2-0006]). [@CD002150-bbs2-0002] and [@CD002150-bbs2-0004] had no missing data; in [@CD002150-bbs2-0005], missing data were balanced between different groups; and in [@CD002150-bbs2-0003] and [@CD002150-bbs2-0006], small percentages of participants were lost to follow‐up.

We considered two trials as having high risk of attrition bias because large numbers of participants from both intervention and control arms were lost to follow‐up (\> 10%) ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0007]).

### Selective reporting {#CD002150-sec3-0024}

We judged all trials as having low risk of reporting bias. These trials adequately reported all prespecified primary and secondary outcomes.

### Other potential sources of bias {#CD002150-sec3-0025}

All trials reported comparable baseline characteristics between groups of participants. We judged one trial to have high risk of bias owing to deviation from the protocol ([@CD002150-bbs2-0007]); in one arm, participants were initially randomized to receive combined doxycycline and rifampicin therapy; and treatment failure occurred in three of eight participants receiving combination therapy.

Effects of interventions {#CD002150-sec2-0010}
------------------------

See: [Table 1](#CD002150-tbl-0001){ref-type="table"}; [Table 2](#CD002150-tbl-0002){ref-type="table"}; [Table 3](#CD002150-tbl-0003){ref-type="table"}

### Comparison 1: doxycycline versus tetracycline {#CD002150-sec3-0026}

Two trials compared doxycycline with tetracycline ([@CD002150-bbs2-0001]; [@CD002150-bbs2-0006]).

One trial reported treatment failure ([@CD002150-bbs2-0006]); results show no significant differences between doxycycline and tetracycline (116 participants, 1 trial; [Analysis 1.1](#CD002150-fig-00101){ref-type="fig"}).

One trial reported the proportion of participants with resolution of fever within 48 hours ([@CD002150-bbs2-0001]); data show little or no difference between doxycycline and tetracycline (risk ratio (RR) 1.14, 95% confidence interval (CI) 0.90 to 1.44; 55 participants, 1 trial; [Analysis 1.2](#CD002150-fig-00102){ref-type="fig"}).

Neither trial reported proportions of participants with resolution of fever within five days.

One trial reported mean time to defervescence ([@CD002150-bbs2-0006]). Results show a mean of 37 hours (standard deviation (SD) ± 26.6 hours) for the tetracycline group and a mean of 34 hours (SD ± 26.5 hours) for the doxycycline group. Study authors reported that the difference was non‐significant via the log‐rank test.

Both trials discussed adverse events but did not formally report the presence or absence of serious adverse events. Gastrointestinal symptoms occurred more frequently with doxycycline than with tetracycline in both trials (not meta‐analysed; [Table 11](#CD002150-tbl-0011){ref-type="table"}).Table 2Adverse events (non‐severe)**StudyInterventionComparisonDoxycyclineTetracycline**[@CD002150-bbs2-0001]Vomiting (8/35)\
Rash (1/35)None reported[@CD002150-bbs2-0006]Gastrointestinal reactions (33/66)Gastrointestinal reactions (10/50)**StudyDoxycyclineMacrolides**[@CD002150-bbs2-0003]Nausea (4/47)\
Diarrhoea (2/47)\
Abdominal discomfort (1/47)\
Raised ALT (5/47)\
Thrombocytopaenia (1/47)***(Azithromycin)***\
Nausea (6/46)\
Vomiting (3/46)\
Raised ALT (4/46)[@CD002150-bbs2-0004]Nausea (2/45)\
Vomiting (1/45)\
Diarrhoea (1/45)\
Abdominal discomfort (2/45)\
Elevated ALT (2/45)\
Skin rash (2/45)\
Oesophageal candidiasis (1/45)***(Telithromycin)***\
Abdominal discomfort (3/47)\
Elevated ALT (4/47)[@CD002150-bbs2-0005]Nausea (3/145)\
Vomiting (22/145)\
Nausea and vomiting (10/145)\
Diarrhoea (1/145)\
Abdominal pain (1/145)\
Rash (1/145)\
Dizziness (1/145)***(Azithromycin)***\
Nausea (1/151)\
Vomiting (10/151)\
Nausea and vomiting (1/151)\
Diarrhoea (1/151)\
Rash (3/151)**StudyDoxycyclineRifampicin**[@CD002150-bbs2-0007]Rash and eosinophilia (1/28)\
\"Severe gastrointestinal (GI) side effects\" (2/28)\
\"Mild GI side effects\" (14/28)Rash and eosinophilia (7/50)\
\"Mild GI side effects\" (18/50)\
Red‐orange discolouration of urine (50/50)[^6]

### Comparison 2: macrolides versus doxycycline {#CD002150-sec3-0027}

Three trials compared macrolide antibiotics with doxycycline ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]).

All three trials reported treatment failure; meta‐analysis of this outcome revealed no significant differences between macrolides and doxycycline (242 participants, 3 RCTs; [Analysis 2.1](#CD002150-fig-00201){ref-type="fig"}). In two of these trials ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]), data show no treatment failures in either arm, and these data did not contribute to the risk ratio in meta‐analysis.

Two trials reported the proportion of participants with resolution of fever within 48 hours ([@CD002150-bbs2-0004]; [@CD002150-bbs2-0005]). Meta‐analysis revealed no differences between macrolides and doxycycline but showed quantitative and qualitative heterogeneity between trials (150 participants, 2 RCTs; [Analysis 2.2](#CD002150-fig-00202){ref-type="fig"}).

Two trials reported the proportion of participants with resolution of fever within five days ([@CD002150-bbs2-0003]; [@CD002150-bbs2-0004]); results show little or no difference between groups (RR 1.05, 95% CI 0.99 to 1.10; 185 participants, 2 RCTs; [Analysis 2.3](#CD002150-fig-00203){ref-type="fig"}; [Figure 3](#CD002150-fig-0003){ref-type="fig"}).Figure 3Forest plot of comparison: 2 Macrolides versus doxycycline, outcome: 2.3 Resolution of fever within five days.

All three trials reported time to defervescence as median times with ranges, which we have presented in [Table 12](#CD002150-tbl-0012){ref-type="table"}. Between studies, median times ranged from 18 to 45 hours; within studies, ranges were also wide. The included studies detected no statistically significant differences between groups.Table 3Time to defervescence: macrolides versus doxycycline**StudyDoxycyclineMacrolideMedianRangeMedianRange**[@CD002150-bbs2-0003]29 hours4 to 176 hours21 hours1 to 120 hours[@CD002150-bbs2-0004]18 hours4 to 105 hours18 hours4 to 176 hours[@CD002150-bbs2-0005]45 hours8 to 118 hours40 hours8 to 136 hours

All three trials reported that no serious adverse events occurred across treatment arms (242 participants, 3 RCTs; [Analysis 2.4](#CD002150-fig-00204){ref-type="fig"}). Gastrointestinal symptoms occurred more frequently with doxycycline than with macrolides in all three trials (not meta‐analysed; [Table 11](#CD002150-tbl-0011){ref-type="table"}).

Subgroup analysis restricted to macrolide subtypes (azithromycin, telithromycin) did not indicate significant differences between findings ([Analysis 5.1](#CD002150-fig-00501){ref-type="fig"} to [Analysis 6.3](#CD002150-fig-00603){ref-type="fig"}).

#### Comparison 2a: macrolides versus doxycycline/chloramphenicol {#CD002150-sec4-0014}

In addition to the three trials comparing macrolide antibiotics with doxycycline, one trial compared azithromycin with doxycycline or chloramphenicol ([@CD002150-bbs2-0002]). We were unable to include this trial in the meta‐analysis as study authors included doxycycline or chloramphenicol as a single arm within the trial and did not report disaggregated data.

For treatment failure, trial authors reported one case in the azithromycin group and zero cases in the doxycycline or chloramphenicol group. We were unable to extract data for resolution of fever at five days or at 48 hours. The median time to defervescence was 36 hours (interquartile range (IQR) 20 to 68 hours) in the azithromycin group and 30 hours (IQR 21 to 48 hours) in the doxycycline/chloramphenicol group. Study authors determined that the difference was non‐significant via the log‐rank test. Adverse event reporting was unclear in this trial.

### Comparison 3: rifampicin versus doxycycline {#CD002150-sec3-0028}

One trial compared rifampicin with doxycycline ([@CD002150-bbs2-0007]). For this analysis, we combined standard‐ and high‐dose rifampicin arms into one group.

Researchers detected no treatment failure in either group (78 participants, 1 trial; [Analysis 3.1](#CD002150-fig-00301){ref-type="fig"}).

For resolution of fever within 48 hours, a higher proportion of participants had resolved fever with rifampicin compared to doxycycline (RR 1.68, 95% CI 1.10 to 2.57; 78 participants, 1 trial; [Analysis 3.2](#CD002150-fig-00302){ref-type="fig"}).

Trial authors did not report the proportions of participants with resolution of fever within five days.

Results show time to defervescence as median times with ranges: 52 hours (range 4 to 108 hours) with doxycycline, 27.5 hours (range 4 to 84 hours) with 600 mg rifampicin, and 22.5 hours (range 3 to 76 hours) with 900 mg rifampicin. Study authors used the Kruskal‐Wallis test to determine that the difference between the doxycycline group and the other two groups was significant.

Researchers did not formally report the presence or absence of serious adverse events, instead stating that there were no \"serious complications\". The trial excluded two participants from the doxycycline arm owing to gastrointestinal side effects. \"Mild\" gastrointestinal side effects occurred more commonly with doxycycline than with rifampicin. Rash and eosinophilia occurred more commonly with rifampicin than with doxycycline ([Table 11](#CD002150-tbl-0011){ref-type="table"}).

As previously discussed, this trial deviated from the protocol after three of eight patients receiving doxycycline and rifampicin combination therapy experienced treatment failure.

### Comparison 4: high‐dose rifampicin versus standard‐dose rifampicin {#CD002150-sec3-0029}

One trial compared 900 mg rifampicin versus 600 mg rifampicin, implementing a change to the original protocol ([@CD002150-bbs2-0007]). Data show no treatment failure in either rifampicin arm (50 participants, 1 trial; [Analysis 4.1](#CD002150-fig-00401){ref-type="fig"}). For proportions of participants with resolution of fever within 48 hours, results show little or no difference between high‐dose and standard‐dose rifampicin (RR 1.03, 95% CI 0.77 to 1.38; 50 participants, 1 trial; [Analysis 4.2](#CD002150-fig-00402){ref-type="fig"}). Researchers did not report the proportions of participants with resolution of fever within five days. We were unable to compare time to defervescence using available data. Trial authors did not formally report the presence or absence of serious adverse events.

Discussion {#CD002150-sec1-0006}
==========

See [Table 1](#CD002150-tbl-0001){ref-type="table"}, [Table 2](#CD002150-tbl-0002){ref-type="table"}, and [Table 3](#CD002150-tbl-0003){ref-type="table"}.

Summary of main results {#CD002150-sec2-0011}
-----------------------

Across the trials included in this review, treatment failure rates were low.

Two trials compared doxycycline versus tetracycline ([Table 1](#CD002150-tbl-0001){ref-type="table"}). For treatment failure, the difference between doxycycline and tetracycline is uncertain (very low‐certainty evidence)*.* Doxycycline compared to tetracycline may make little or no difference in resolution of fever within 48 hours (low‐certainty evidence) or in time to defervescence (low‐certainty evidence)*.* We were unable to extract data for other outcomes.

Three trials compared doxycycline versus macrolides (azithromycin and telithromycin; [Table 2](#CD002150-tbl-0002){ref-type="table"}). For most outcomes, including treatment failure, resolution of fever within 48 hours, time to defervescence, and serious adverse events, we are uncertain whether results show a difference between doxycycline and macrolides (very low‐certainty evidence). Macrolides compared to doxycycline may make little or no difference in the proportion of patients with resolution of fever within five days (low‐certainty evidence). Another trial compared azithromycin to doxycycline or chloramphenicol in children, but we were unable to disaggregate data for the doxycycline/chloramphenicol group.

One trial compared doxycycline to rifampicin ([Table 3](#CD002150-tbl-0003){ref-type="table"}). For all outcomes, we are uncertain whether results show a difference between doxycycline and rifampicin (very low‐certainty evidence). Of note, this trial deviated from the protocol after three out of eight patients who received doxycycline and rifampicin combination therapy experienced treatment failure.

Across trials, mild gastrointestinal side effects appeared to be more common with doxycycline than with comparator drugs; this finding does not derive from meta‐analysis but from narrative analysis of [Table 11](#CD002150-tbl-0011){ref-type="table"}. When reported, serious adverse events were few.

Overall completeness and applicability of evidence {#CD002150-sec2-0012}
--------------------------------------------------

All included studies were reported from Malaysia, Thailand, and Korea; we excluded several studies from China because they were not RCTs. Given that there may be geographical variation in antibiotic susceptibility across the \'tsutsugamushi triangle\', applicability of findings may be limited.

Factors specific to the antibiotics included in this review may influence the applicability of evidence. In general, doxycycline is preferred over tetracycline because of its more convenient dosing schedule. Production of the macrolide antibiotic telithromycin was discontinued by the manufacturer in 2016, and before this, safety warnings had been issued; therefore this agent no longer represents a viable treatment option. In tuberculosis endemic areas, rifampicin monotherapy carries the risk of inducing rifampicin resistance in undiagnosed tuberculosis. The dose schedules of included antibiotics varied across trials.

Findings with respect to rifampicin have emerged from only one trial ([@CD002150-bbs2-0007]), which provided low‐certainty evidence of very limited applicability. Of concern, doxycycline and rifampicin combination therapy resulted in a high rate of treatment failures, but the reasons for this are unclear and are not discussed further by the study author team. Although study authors suggest that rifampicin should be considered in cases where *Orientia tsutsugamushi* is resistant to doxycycline, it is unclear epidemiologically whether such resistance is clinically significant.

The included trials employed a variety of diagnostic techniques and recruited patients at different points within the diagnostic pathway. Some of the participants included in this review may represent misdiagnoses, which also may limit the applicability of findings.

### Certainty of the evidence {#CD002150-sec3-0030}

We have included in this update seven trials, which represented 548 participants, with dates ranging from 1978 to 2015. Most trials were open‐label and did not report clear allocation concealment or randomization techniques. Results were imprecise owing to the small numbers of participants included for each comparison. Therefore, the body of evidence in relation to treatment of scrub typhus is of low or very low certainty.

Potential biases in the review process {#CD002150-sec2-0013}
--------------------------------------

We attempted to minimize bias in the review process by conducting a comprehensive search of all published and non‐published literature with no language restrictions. Two review authors assessed the eligibility of studies, extracted data, and independently judged risk of bias. We resolved disagreements by consensus and by consultation with the fourth review author. We altered our inclusion criteria for this updated review. In particular, we excluded studies that used the Weil‐Felix test as the sole measure of laboratory confirmation, given poor specificity. As a result, we excluded one trial that had been included in the previous review ([@CD002150-bbs2-0015]).

Agreements and disagreements with other studies or reviews {#CD002150-sec2-0014}
----------------------------------------------------------

Our findings are in agreement with those of a recently published meta‐analysis ([@CD002150-bbs2-0044]), which concluded that evidence is insufficient to support recommending one drug over the others examined here. However, authors of the meta‐analysis included trials that employed the Weil‐Felix test as the sole diagnostic tool, and the poor specificity associated with this test may raise the level of heterogeneity amongst pooled participants.

Authors\' conclusions {#CD002150-sec1-0007}
=====================

Tetracycline, doxycycline, azithromycin, and rifampicin are effective treatment options for scrub typhus that have been associated with few treatment failures. Chloramphenicol remains a treatment option, but we could not include this agent in direct comparisons for this review.For specific outcomes, low‐certainty evidence suggests there may be little or no difference between tetracycline, doxycycline, and azithromycin as treatment options. In the light of very low‐certainty evidence for rifampicin and the risk of inducing resistance in undiagnosed tuberculosis, clinicians should not regard this agent as a first‐line treatment option but should consider it as a second‐line treatment option after exclusion of active tuberculosis.Further research should include adequately powered trials of doxycycline versus azithromycin or other macrolides, trials of other candidate antibiotics including rifampicin, and trials of treatment of severe scrub typhus. Researchers should standardize diagnostic techniques and reporting of clinical outcomes to allow robust comparisons.

The Academic Editor of this review update was Dr Geraint Davies.

The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK government for the benefit of low‐ and middle‐income countries (project number 300342‐104). The views expressed do not necessarily reflect the UK government's official policies.

**Protocol sectionRefreshed protocol**Background and research questionWe have updated information in the background to follow the advised Cochrane/MECIR subheading structureWe have included further information on diagnostics and have elaborated on antibiotics and antibiotic resistanceThe main review question remains relevantThe existing PICO remains relevant. We have added clarification to the diagnostic criteria used to define cases of scrub typhusWe have identified new concerns in relation to the use of quinolone antibiotics that were not covered by the original reviewWe have not identified changes in core standards or in standardized core outcome setsWe are aware of no patient‐reported outcomesWe do not think that any changes to studies may warrant stricter inclusion criteriaMethodsWe have updated the description of the risk of bias toolWe have added a plan to summarize the evidence using the GRADE approach

This table was approved by the CIDG editorial team on 16 March 2018.

Comparison 1Doxycycline versus tetracyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD002150-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Doxycycline versus tetracycline, Outcome 1 Treatment failure.1116Risk Ratio (M‐H, Fixed, 95% CI)6.85 \[0.38, 124.38\][2 Resolution of fever within 48 hours](#CD002150-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Doxycycline versus tetracycline, Outcome 2 Resolution of fever within 48 hours.155Risk Ratio (M‐H, Fixed, 95% CI)1.14 \[0.90, 1.44\]

Comparison 2Macrolides versus doxycyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD002150-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Macrolides versus doxycycline, Outcome 1 Treatment failure.3242Risk Ratio (M‐H, Fixed, 95% CI)2.71 \[0.12, 63.84\][2 Resolution of fever within 48 hours](#CD002150-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Macrolides versus doxycycline, Outcome 2 Resolution of fever within 48 hours.2150Risk Ratio (M‐H, Random, 95% CI)0.81 \[0.32, 2.03\][3 Resolution of fever within 5 days](#CD002150-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Macrolides versus doxycycline, Outcome 3 Resolution of fever within 5 days.2185Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.99, 1.10\][4 Serious adverse events](#CD002150-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Macrolides versus doxycycline, Outcome 4 Serious adverse events.3242Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 3Rifampicin versus doxycyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD002150-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Rifampicin versus doxycycline, Outcome 1 Treatment failure.178Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][2 Resolution of fever within 48 hours](#CD002150-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Rifampicin versus doxycycline, Outcome 2 Resolution of fever within 48 hours.178Risk Ratio (M‐H, Fixed, 95% CI)1.68 \[1.10, 2.57\][3 Serious adverse events](#CD002150-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Rifampicin versus doxycycline, Outcome 3 Serious adverse events.178Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 4High rifampicin dose versus standard rifampicin doseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Failure](#CD002150-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 High rifampicin dose versus standard rifampicin dose, Outcome 1 Failure.150Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][2 Resolution of fever within 48 hours](#CD002150-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 High rifampicin dose versus standard rifampicin dose, Outcome 2 Resolution of fever within 48 hours.150Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.77, 1.38\][3 Serious adverse events](#CD002150-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 High rifampicin dose versus standard rifampicin dose, Outcome 3 Serious adverse events.150Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 5Macrolide subgroup: azithromycin versus doxycyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD002150-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Macrolide subgroup: azithromycin versus doxycycline, Outcome 1 Treatment failure.2150Risk Ratio (M‐H, Fixed, 95% CI)2.71 \[0.12, 63.84\][2 Resolution of fever within 48 hours](#CD002150-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 Macrolide subgroup: azithromycin versus doxycycline, Outcome 2 Resolution of fever within 48 hours.2150Risk Ratio (M‐H, Random, 95% CI)0.81 \[0.32, 2.03\][3 Resolution of fever within 5 days](#CD002150-fig-00503){ref-type="fig"}Analysis 5.3Comparison 5 Macrolide subgroup: azithromycin versus doxycycline, Outcome 3 Resolution of fever within 5 days.193Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.98, 1.17\][4 Serious adverse events](#CD002150-fig-00504){ref-type="fig"}Analysis 5.4Comparison 5 Macrolide subgroup: azithromycin versus doxycycline, Outcome 4 Serious adverse events.2150Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 6Macrolide subgroup: telithromycin versus doxycyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD002150-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Macrolide subgroup: telithromycin versus doxycycline, Outcome 1 Treatment failure.192Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][2 Resolution of fever within 5 days](#CD002150-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Macrolide subgroup: telithromycin versus doxycycline, Outcome 2 Resolution of fever within 5 days.192Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.96, 1.09\][3 Serious adverse events](#CD002150-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Macrolide subgroup: telithromycin versus doxycycline, Outcome 3 Serious adverse events.192Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

**DateEventDescription**20 September 2018New citation required and conclusions have changedWe updated the literature search to 8 January 2018, included one new trial ([@CD002150-bbs2-0002]), and excluded one previously included trial ([@CD002150-bbs2-0015]). The conclusions changed to reflect certainty of evidence and to present more guarded conclusions about rifampicin.20 September 2018New search has been performedThe review author team changed. The review author team revised the protocol, which was approved by the CIDG editorial team on 16 March 2018 (see [Appendix 1](#CD002150-sec2-0015){ref-type="app"}). We reworded the objectives: \"To assess and compare the effects of different antibiotic regimens for treatment of scrub typhus\", replaces \"To evaluate antibiotic regimens for treating scrub typhus\". We assessed the certainty of the evidence using the GRADE approach.

Protocol first published: Issue 2, 2000 Review first published: Issue 2, 2000

**DateEventDescription**27 May 2010New search has been performedNew search performed and new studies added. Primary outcomes amended8 June 2009AmendedReview converted to new review format3 January 2007New citation required and conclusions have changedSubstantive amendments made

The review author team revised the protocol, which was approved by the CIDG editorial team on 16 March 2018 (see [Appendix 1](#CD002150-sec2-0015){ref-type="app"}). Owing to small numbers of trials per each comparison, we did not perform subgroup analysis according to geographical setting (which may influence antibiotic susceptibility), dates of the study (before or after antibiotic resistance was first reported), participant age (children versus adults), or dose, frequency, and duration of treatment. We also did not perform sensitivity analysis to assess robustness of our results after restricting analysis to studies with low risk of bias. Otherwise, we fulfilled all proposed changes as shown in [Appendix 1](#CD002150-sec2-0015){ref-type="app"}.

Upon receiving editorial feedback on the first draft of this review, we changed \'resolution of fever within five days\' from a primary to a secondary outcome.

Characteristics of included studies \[ordered by study ID\] {#CD002150-sec2-0018}
===========================================================

[@CD002150-bbs2-0001]MethodsRCT\
Duration: 11 months (September 1976 to July 1977)\
Adverse event monitoring: patient reportParticipantsAdults with suspected scrub typhus (randomized before confirmed diagnosis)\
Number randomized: 149\
Inclusion criteria: adults ≥ 18 years with febrile illness\
Exclusion criteria: previous tetracycline and chloramphenicol; history of allergy to tetracycline; jaundice; pregnancy; clinical and laboratory evidence of non‐rickettsial disease\
Diagnosis: isolation of *Rickettsia tsutsugamushi;* OR a 4‐fold or greater rise in IFA titre to at least 1:200 or in static titre of 1:800 or more; OR a 4‐fold or greater rise in Proteus OXK agglutination test titre to at least 1:200InterventionsDoxycycline 200 mg single oral dose\*Tetracycline 500 mg 6‐hourly for 7 days\*\
\*Clinicians gave additional treatment at their discretion if no improvement within 48 hours, or if clinical and laboratory evidence of alternative diagnosisOutcomesResolution of fever within 48 hoursDisappearance of symptomsRelapseSide effectsNotesCountry: Malaysia\
Setting: district hospital\
Date: September 1976 to July 1977\
Funding: US Army Medical Research and Development Command, Washington, DC, and Ministry of Health, Malaysia\
Follow‐up: 14 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Volunteers were randomly assigned\"; no further detailsAllocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesUnclear riskNo details reportedIncomplete outcome data (attrition bias) All outcomesHigh risk149 randomized before confirmed diagnosis. 65 with confirmed diagnosis of scrub typhus. 10 excluded (mixed infection). 55 included in final analysis (84.6% of participants with a confirmed diagnosis)Selective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0002]MethodsRCT\
Duration: 2 years, 11 months (June 2010 to May 2013)\
Adverse event monitoring: patient reportParticipantsChildren with positive scrub typhus RDT\
Number randomized: 57\
Inclusion criteria: hospitalized children ≤ 15 years of age; clinical manifestations compatible with scrub typhus; confirmatory laboratory tests\
Exclusion criteria: allergy to study drug; severe clinical complications (hypotension, coma, respiratory failure, acute renal failure with renal replacement therapy); anti‐microbial therapy \< 7 days pre‐admission\
Laboratory diagnosis: dipstick RDT (SD Bioline Tsutsugamushi test)InterventionsAzithromycin: oral sachets 20 mg/kg/dose initially, maximum 1000 mg first day followed by 10 mg/kg/dose, maximum 500 mg for 2 days (n = 29)\*Chloramphenicol: intravenous 100 mg/kg/d 6‐hourly (n = 9; patients aged \< 8 years)^†^Doxycycline: oral 2.2 mg/kg/dose (maximum 100 mg/dose) 12‐hourly day 1; same dose once daily for at least 5 days or until defervescence (3 days; n = 19)^†^\
\*Changed to \"standard treatment\" if clinical failure\
†Children under 8 received chloramphenicol; children 8 and older received doxycyclineOutcomesCure, defined as defervescence\* within 72 hoursFailure, defined as persistence of fever \> 72 hours or complicationsTime to defervescence\*Relapse (within 30 days)Adverse events\
\*Temperature \< 37.3°C maintained for \> 48 hoursNotesCountry: Thailand\
Setting: tertiary hospital, paediatrics unit\
Funding: Chiangrai Prachanukroh Hospital fund\
Follow‐up: 1 month after discharge***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomization; no further detailsAllocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesHigh risk\"Open‐label\"; no further detailsIncomplete outcome data (attrition bias) All outcomesLow risk57 randomized after RDT positive diagnosis. No missing data (57/57)Selective reporting (reporting bias)Low riskAll prespecified outcomes adequately reported. Adverse events defined as those \"related to the administration of the antibiotic\"Other biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0003]MethodsRCT\
Duration: 1 year, 2 months (September 2002 to November 2003)\
Adverse event monitoring: patient reportParticipantsAdults with suspected scrub typhus (randomized before confirmed diagnosis)\
Number randomized: 99\
Inclusion criteria: fever (oral temperature ≥ 38°C); eschar or a maculopapular skin rash with 2 of: headache, generalized weakness, myalgia, abdominal discomfort, coughing, or nausea\
Exclusion criteria: hypersensitivity to study drugs; pregnancy; severe complications (shock requiring vasopressor therapy for \> 1 hour, disturbed consciousness level, respiratory failure, and renal failure with immediate dialysis); antibiotics with potential anti‐rickettsial activity within previous 2 days\
Laboratory diagnosis: IFA with specific IgM ≥ 1:10; OR*\>* 4‐fold increased titres in paired serum specimensInterventionsAzithromycin 500 mg single oral dose (n = 47)Doxycycline 200 mg once daily for 7 days (n = 46)OutcomesTime to defervescence\*Resolution of fever within 5 days (\"cure\")Treatment failure, defined as persistence of feverRelapse (within 30 days)Adverse events\
\*Temperature \< 37.3°C maintained for \> 48 hoursNotesCountry: Republic of Korea\
Setting: tertiary hospital\
Funding: Chungnam National University Hospital (Daejeon, South Korea)\
Follow‐up: 1 month after discharge***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random sequencesAllocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesHigh risk\"Open‐label\"; no further detailsIncomplete outcome data (attrition bias) All outcomesLow risk99 randomized before confirmed diagnosis. 6 excluded after randomization (combined infection, vomiting, medication error). 93 completed treatment and included in final analysis. 75 with laboratory‐confirmed diagnosisSelective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0004]MethodsQuasi‐RCT\
Duration: 4 months (September to December 2005)\
Adverse event monitoring: patient reportParticipantsAdults with suspected scrub typhus (randomized before confirmed diagnosis)\
Number randomized: 92\
Inclusion criteria: fever \> 37.5°C; eschar or a maculopapular skin rash with 2 of: headache, malaise, myalgia, coughing, nausea, or abdominal discomfort\
Exclusion criteria: unable to take oral medications; pregnancy; hypersensitivity to trial drugs, antibiotics with potential anti‐rickettsial activity within previous 2 days; severe scrub typhus (shock requiring vasopressor therapy for longer than 1 hour, a stuporous or comatose level of consciousness, respiratory failure requiring mechanical ventilation, or renal failure requiring immediate dialysis); mixed infection\
Laboratory diagnosis: IFA with specific IgM \> 1:80; OR *\>* 4‐fold increased titres in paired serum specimensInterventionsTelithromycin: 800 mg daily for 5 days (n = 47)Doxycycline: 200 mg daily for 5 days (n = 45)OutcomesTime to defervescence\* (\"fever clearance time\")Resolution of fever within 5 days (\"cure\")Treatment failure, defined as persistence of feverRelapse (within 30 days)Adverse eventsNotesCountry: Republic of Korea\
Setting: university hospital and 2 community hospitals\
Funding: Sanofi‐Aventis Korea Co., Ltd.; The Clinical Medicine Research Institute at Chosun University Hospital\
Follow‐up: 4 weeks after discharge***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskRandomized by last digit of resident registration number (odd numbers assigned to doxycycline, even numbers assigned to telithromycin)Allocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesHigh risk\"Open‐label\"; no further detailsIncomplete outcome data (attrition bias) All outcomesLow risk92 randomized before confirmed diagnosis. 92 patients included in final analysis. 76 with laboratory‐confirmed diagnosisSelective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0005]MethodsRCT\
Duration: 1 year, 6 months (July 2003 to January 2005)\
Adverse event monitoring: patient reportParticipantsAdults and adolescents with acute undifferentiated fever (subsequent diagnoses included leptospirosis, scrub typhus, murine typhus, mixed infections)\
Number randomized: 296 (57 patients with subsequent diagnosis of scrub typhus)\
Inclusion criteria: age \> 14 years; oral temperature ≥ 38°C for \< 15 days; no obvious focus of infection\
Exclusion criteria: inability to take oral medications; pregnancy/breastfeeding; allergy to study drugs; concurrent infection; anti‐rickettsial drugs \< 48 hours before enrolment\
Laboratory diagnosis: IFA (microimmunofluorescence) with specific IgM and/or IgG \> 1:400; OR *\>* 4‐fold increased titres in paired serum specimensInterventionsAzithromycin 1 g daily for 3 days, followed by 500 mg daily for 2 days (n = 30)Doxycycline 200 mg day 0, then 100 mg 12‐hourly for 7 days (n = 27)OutcomesResolution of fever within 5 days (\"cure\")Treatment failure, defined as persistence of fever or development of complications after 48 hours of treatmentTime to defervescence\*Adverse events\
\*Temperature \< 37.5°C maintained for \> 2 measurements without anti‐pyreticsNotesCountry: Thailand\
Setting: 4 hospitals\
Funding: Thailand Research Fund, Ministry of Public Health, Thailand, and the Welcome Trust of Great Britain\
Follow‐up: 15 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskIndependent, computer‐generated, simple random allocation sequencesAllocation concealment (selection bias)Low riskCentral randomization; sealed, opaque envelopesBlinding (performance bias and detection bias) All outcomesHigh riskOpen‐label. Outcome assessment \"independent\". Statistician blindedIncomplete outcome data (attrition bias) All outcomesLow risk296 randomized. 43 excluded after randomization owing to prior antibiotics. 89 lost to follow‐up (uncertain diagnosis). 296 included in final analysis; of these 57 participants had confirmed scrub typhus. Missing data balanced between final diagnosis groupsSelective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0006]MethodsRCT\
Duration: 1 year, 1 month (October 1991 to November 1992)\
Adverse event monitoring: patient report.ParticipantsAdults with positive scrub typhus IFA\
Number randomized: 129\
Inclusion criteria: age ≥ 18 years; acute febrile illness with high fever, rash, and eschar\
Exclusion criteria: subsequent unconfirmed diagnosis; allergy to study drugs; received study drugs within last 72 hours; raised serum creatinine; pregnancy or lactation\
Laboratory diagnosis: IFA with specific IgG \> 1:80; OR *\>* 4‐fold increased titres in paired serum specimensInterventionsDoxycycline oral 100 mg 12‐hourly for 3 days (n = 66)Tetracycline oral 500 mg 12‐hourly for 7 days (n = 50)OutcomesCure (resolution of fever, signs, and symptoms by end of course)Treatment failure (persistence of fever/signs and symptoms by end of course)Time to defervescence\*Relapse (4 weeks)Time to resolution of symptomsAdverse events\
\*Temperature \< 37.3°C maintained for \> 48 hoursNotesCountry: Korea.\
Setting: 8 branch hospitals\
Funding: Asian Institute for Life Science\
Follow‐up: 4 weeks***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentrally computer‐generated random ordersAllocation concealment (selection bias)Unclear risk\'\'Central randomisation\'\'; no further detailsBlinding (performance bias and detection bias) All outcomesHigh riskNon‐blindedIncomplete outcome data (attrition bias) All outcomesLow risk129 randomized. 13 excluded owing to negative or indeterminate diagnosis. 116 included in final analysis (90% of those randomized)Selective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasLow riskNo obvious other sources of bias[@CD002150-bbs2-0007]MethodsRCT\
Duration: no details\
Adverse event monitoring: patient reportParticipantsAdults with positive scrub typhus RDT\
Number: 126\
Inclusion criteria: adults; ambulatory mild scrub typhus; ability to take oral medication\
Exclusion criteria: severe disease (hypotension, shock, impaired consciousness, or pulmonary dysfunction); coinfection or other febrile illness; vomiting; serum bilirubin \> 25.7 μmol/L; serum ALT \> 100 U/L; anti‐rickettsial drugs \< 48 hours before enrolment\
Laboratory diagnosis: screened with dot‐blot ELISA rapid test. Confirmed with indirect immunoperoxidase test: IgM \> 1:400, IgG \> 1:1600InterventionsDoxycycline monotherapy oral 200 mg day 0, then 100 mg 12‐hourly for 7 days (n = 28)Rifampicin 300 mg 12‐hourly for 7 days (n = 26)Combined doxycycline 100 mg 12‐hourly and rifampicin 300 mg 12‐hourly for 7 days (n = 11)\*Rifampicin 450 mg 12‐hourly for 7 days (n = 24)\*\
\*In a change to the protocol, arm 4 (450 mg rifampicin) replaced arm 3 (combined therapy) after 1 year owing to protracted fever.OutcomesTime to defervescence\* (\"fever clearance time\")Treatment failure (remaining pyretic after therapy)Relapse (1 month)Resolution of fever within 48 hoursAdverse events\
\*Temperature \< 37.3°C maintained for \> 48 hours without anti‐pyreticsNotesCountry: Thailand\
Setting: tertiary hospital\
Funding source: US Army Research and Material Command and the Royal Thai Army\
Follow‐up: 1 month during first year of study; 2 weeks in following years***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Patients were randomly assigned\"; no further detailsAllocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesUnclear riskDescribes efforts to \"mask\" investigators from evidence of drug allocation in the form of red discolouration of body fluids but provides limited detailsIncomplete outcome data (attrition bias) All outcomesHigh risk357 of 2090 with positive RDT; 231 excluded before randomization as \"ineligible\"; 126 seropositive and randomized. 32 excluded after randomization; 5 excluded as diagnosis not confirmed. 78 completed protocol and were analysed (67.8% of those randomized)Selective reporting (reporting bias)Low riskAll prespecified outcomes adequately reportedOther biasHigh riskDeviation from the study protocol. Participants initially randomized to receive combined doxycycline and rifampicin therapy; 3 of 8 participants receiving combination therapy experienced failed treatment. Combined therapy arm changed to high‐dose rifampicin arm[^7]

Characteristics of excluded studies \[ordered by study ID\] {#CD002150-sec2-0019}
===========================================================

StudyReason for exclusion[@CD002150-bbs2-0008]A retrospective analysis, not an RCT. Diagnosis based only on Weil‐Felix reaction[@CD002150-bbs2-0009]A retrospective analysis, not an RCT. Diagnosis based only on Weil‐Felix reaction[@CD002150-bbs2-0010]A retrospective analysis, not an RCT. Diagnosis based only on Weil‐Felix reaction[@CD002150-bbs2-0011]A retrospective analysis, not an RCT. Diagnosis based only on Weil‐Felix reaction[@CD002150-bbs2-0012]Diagnosis based only on Weil‐Felix reaction\
Unclear study design. Participants were randomly allocated to 5 treatment groups, but study authors did not describe the randomization process.[@CD002150-bbs2-0013]Assessed efficacy for prevention rather than for treatment[@CD002150-bbs2-0014]Diagnosis based only on Weil‐Felix reaction\
Unclear study design. Participants were randomly allocated to 2 treatment groups, but study authors did not describe detailed randomization methods. Whether it is a real RCT needs clarification.[@CD002150-bbs2-0015]Diagnosis based only on Weil‐Felix reaction[@CD002150-bbs2-0016]Assessed efficacy for prevention rather than for treatment[@CD002150-bbs2-0017]Diagnosis based only on Weil‐Felix reaction\
Unclear study design. Participants were randomly allocated to 2 treatment groups, but study authors did not describe detailed randomization methods. Whether it is a real RCT needs clarification.[@CD002150-bbs2-0018]Diagnosis based only on Weil‐Felix reaction\
Unclear study design. Participants were randomly allocated to 2 treatment groups, but study authors did not describe detailed randomization methods.[@CD002150-bbs2-0019]Diagnosis based only on Weil‐Felix reaction\
A retrospective analysis, not an RCT[@CD002150-bbs2-0020]Diagnosis based only on Weil‐Felix reaction[^8]

Characteristics of ongoing studies \[ordered by study ID\] {#CD002150-sec2-0020}
==========================================================

[@CD002150-bbs2-0021]Trial name or titleOral Doxycycline Versus Oral Azithromycin in the Treatment of Scrub and Murine Typhus in LaosMethodsRandomized controlled trial (RCT)Participants**Inclusion criteria**\
Adult (\> 15 years) non‐pregnant patients with suspected typhus. Suspected typhus will be defined as undifferentiated fever (aural temperature \> 37.5°C), with or without an eschar, with a positive scrub typhus lateral flow IgM result or a murine typhus IgM Dip‐Sticks resultWritten informed consent to participate in the studyAbility to stay in hospital for duration of treatment (up to 7 days) and high likelihood of completing at least 4 weeks of follow‐upAbility to take oral medicationNegative urinary pregnancy test for all women of child‐bearing ageNone of the exclusion criteria\
**Exclusion criteria**\
Known hypersensitivity to tetracycline, doxycycline, or azithromycinAdministration of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, or azithromycin during the preceding weekPregnancy or breast‐feedingContraindications to doxycycline: severe hepatic impairment, known systemic lupus erythematosus (SLE)Contraindications to azithromycin: severe hepatic impairmentSevere typhus defined as:Reduced level of consciousnessClinical jaundiceShock (blood pressure (BP) systolic \< 80 mmHg)Vomiting sufficient to disallow the use of oral medicationClinical or radiological evidence of lung involvementClinical evidence of meningitis/encephalitis or the need for a lumbar puncture (LP)Any other syndrome that in the opinion of the admitting doctor constitutes severe typhus (reason must be stated)InterventionsOral doxycycline 100 mg every 12 hours for 7 days (after a 200‐mg loading dose)Doxycycline 100 mg every 12 hours for 3 days (after a 200‐mg loading dose)Oral azithromycin 500 mg on day 1, then 250 mg every 24 hours for 2 more daysOutcomesFever clearance timeFrequencies of treatment failureFrequencies of relapseTreatment failure frequencyRelapse frequencyStarting date4 August 2003\
End of follow‐up: 31 December 2009Contact informationDr. Paul Newton\
paul\@tropmedres.ac; Ministry of Health, Mahosot Hospital, Mahosot Road, Vientiane, LaosNotesLocation: Mahosot Hospital, Vientiane, Laos\
Registration number: [@CD002150-bbs2-0021]\
Source of funding: The Wellcome Trust (UK) (grant ref: 066828)[@CD002150-bbs2-0022]Trial name or titleControlled Trial: 5‐Day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub TyphusMethodsMulti‐centre randomized open‐label clinical trialParticipants**Inclusion criteria**\
Adult patients aged 18 years and older presenting with fever ≥ 37.5°C, eschar, or maculopapular rash and with at least 2 of the following: headache, malaise, myalgia, coughing, nausea, and abdominal discomfort\
**Exclusion criteria**\
Inability to take oral medicationsPregnancyHypersensitivity to trial drugsPrevious drug therapy with potential anti‐rickettsial activity within 48 hours before admissionSevere scrub typhus (shock requiring vasopressor therapy for \> 1 hour, comatose level of consciousness, respiratory failure requiring mechanical ventilation, or renal failure requiring immediate dialysis)Interventions5‐day course of telithromycin versus doxycyclineOutcomesFever clearance timeStarting dateSeptember 2005\
Last update posted: 12 July 2006Contact informationProf. Dong‐Min Kim\
[drongkim\@chosun.ac.kr](drongkim@chosun.ac.kr); Chosun University Hospital, Republic of KoreaNotesLocation: Chosun University Hospital, Republic of Korea\
Registration number: Telit_L\_00276\
Sources of funding: Chosun University Hospital[@CD002150-bbs2-0023]Trial name or titleControlled Trial: 5‐Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub TyphusMethodsRCTParticipants**Inclusion criteria**\
Adults 18 years of age or olderFever higher than 37.5˚CConcurrent presence of eschar or a maculopapular skin rash; and clear presence of more than 2 symptoms such as headache, malaise, myalgia, coughing, nausea, and abdominal discomfortPatients hospitalized between 2006 and 2009 at Chosun University Hospital in Gwangju, South Korea, or at one of its 2 community‐based affiliated hospitals, all of which are located in southwestern Korea\
**Exclusion criteria**\
Inability to take oral medicationsPregnancyHypersensitivity to trial drugsPrevious drug therapy with potential anti‐rickettsial activity (for example, rifampicin, chloramphenicol, macrolides, fluoroquinolones, tetracyclines) within 48 hours before admissionSevere scrub typhus (shock requiring vasopressor therapy for longer than 1 hour)Stuporous or comatose level of consciousnessRespiratory failure requiring mechanical ventilation or renal failure requiring immediate dialysisFor the differential diagnosis of scrub typhus from other diseases with similar symptoms (for example, murine typhus, leptospirosis, haemorrhagic fever with renal syndrome, systemic lupus erythematosus), patients underwent diagnostic tests. We thus excluded patients with concurrent infections at risk for causing different outcomesInterventions5‐day rifampin therapy5‐day doxycycline therapyOutcomesFever clearance timeCureFailureRelapseStarting dateSeptember 2006\
Expected completion: December 2009\
Unknown recruitment statusContact informationProf. Dong‐Min Kim [drongkim\@chosun.ac.kr](drongkim@chosun.ac.kr); Chosun University Hospital, Kwangju, Jeollanamdo, South KoreaNotesLocation: Chosun University Hospital, or one of its 2 community‐based affiliated hospitals, all of which are located in southwestern Korea\
Study ID number: [@CD002150-bbs2-0023][@CD002150-bbs2-0024]Trial name or titleScrub Typhus Antibiotic Resistance Trial (START)MethodsProspective, open‐label, RCTParticipants**Inclusion criteria**\
Age ≥ 15 yearsHospitalization with acute fever \> 37.5°C for ≤ 14 days or admission with a history of fever ≤ 14 days and developing fever within 24 hours after hospitalizationClinically suspected scrub typhus: acute undifferentiated fever with no clear focus of infection (negative malaria blood smear and/or negative malaria RDT). Patients may have 1 or a combination of symptoms and signs such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea, and abdominal discomfort.Positive scrub typhus RDT (Scrub Typhus Detect IgM RDT, InBios International, Seattle, Washington, USA) and/or positive PCR‐based detection of *Orientia tsutsugamushi* DNA from the admission blood sampleWritten informed consentAbility to take oral medication\
**Exclusion criteria**\
Hypersensitivity to trial drugsAdministration of anti‐microbial therapy within 7 days before the trialPregnancy or breast‐feedingEstablished infection (for example, acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis)Confirmed TB or TB treatment in ≤ 6 monthsSevere disease for which the clinical team thinks that current treatment is not enough (for example, IV chloramphenicol and/or PO/NG rifampicin)Long‐term use of immunosuppressants (for example, steroids, chemotherapy, TNF‐inhibitors) and use of HAART for HIV patientsSystemic lupus erythematosus and myasthenia gravisInterventionsDoxycycline 100 mg PO every 12 hours for 7 days (after loading dose, 200 mg PO)Doxycycline 100 mg PO every 12 hours for 3 days (after loading dose, 200 mg PO)Azithromycin 500 mg PO every 24 hours on days 2 and 3 (after loading dose, 1000 mg PO on day 1)Outcomes**Primary**\
Fever clearance time\
**Secondary**\
Resolution of bacteraemia in relation to drug plasma levelOccurrence of severe disease or treatment failure/relapsePresence of in vitro anti‐microbial resistanceGenotyping of clinical *Orientia tsutsugamushi* isolatesAntigen‐specific positive cellular and humoral immune responsesStarting date17 March 2017.\
Last update posted: 14 December 2017\
Expected completion time: October 2019Contact informationAssoc. Prof. Daniel Paris\
[parigi\@tropmedres.ac](parigi@tropmedres.ac); Mahidol Oxford Tropical Medicine Research Unit, Bangkok, ThailandNotesLocation: Shoklo Malaria Research Unit (SMRU), Chiangrai Prachanukroh Hospital, Thailand\
Study ID number: START\
Source of funding: University of Oxford, Shoklo Malaria Research Unit and Chiangrai Prachanukroh Hospital[^9]

Iman El Sayed: prepared initial drafts of background and methods; selected studies; extracted data; synthesized data in [@CD002150-bbs2-0036]; and prepared initial drafts of results and \'Summary of findings\' tables.

Qin Liu: selected studies and extracted data; assessed risk of bias; contributed to \'Summary of findings\' tables; and contributed to the discussion.
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REVIEW HISTORY (started 4 March 2002). 4 March 2002: updated review received by editorial base: included a new trial ([@CD002150-bbs2-0007]); responded to comments received from Assistant Editor and statistician: (1) made slight change to the objective; (2) changed adverse outcomes from \"Number and seriousness of side effects\" to \"Number of adverse events\"; and (3) used risk ratio for binary outcomes (previously Peto odds ratio).

June 2010: updated review received by editorial base: (1) amended primary outcomes so no longer include \"death\" as a primary outcome; and (2) added new trials.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^Downgraded by 1 due to serious risk of bias. [@CD002150-bbs2-0006] had unclear allocation concealment and was not blinded. ^b^Downgraded by 2 due to very serious imprecision. Sample size and number of events were small and did not meet optimal information size. ^c^Downgraded by 1 due to serious risk of bias. [@CD002150-bbs2-0001]had high risk of attrition bias, although this was not likely to differentially affect treatment groups, and unclear risk of bias from sequence generation, allocation concealment, and blinding. ^d^Downgraded by 1 due to serious imprecision. The 95% CI overlaps no effect (that is, CI includes RR of 1.0), and the CI fails to exclude appreciable benefit. ^e^Downgraded by 1 for serious imprecision: [@CD002150-bbs2-0006] was underpowered to detect this effect.

[^3]: ^a^Derived from risk across all included trials in patients treated with doxycycline (four events in 212 patients). ^b^Downgraded by 1 due to serious risk of bias: all three included trials were open‐label; [@CD002150-bbs2-0004] was quasi‐randomized. ^c^Downgraded by 2 due to very serious imprecision: sample size and number of events were small, and confidence intervals cross the line of no effect. Two trials reported no events in either treatment arm, so they do not contribute to the risk ratio. ^d^Downgraded by 2 due to very serious inconsistency: data show quantitative and qualitative inconsistency between trials. ^e^Downgraded by 1 due to serious inconsistency: [Kim 2004](Kim 2004) gave azithromycin as a single oral dose; [Kim 2007](Kim 2007) gave telithromycin for five days.

[^4]: ^a^Downgraded by 2 due to very serious risk of bias. In [@CD002150-bbs2-0007], sequence generation, allocation concealment, and blinding were unclear; risk of attrition bias with incomplete follow‐up was high (67.8%), as was risk of other bias due to deviation from the trial protocol. ^b^Downgraded by 2 due to very serious imprecision. Number of events is very small and does not meet optimum information size (\< 300 events), and the sample size is small. ^c^Downgraded by 1 due to serious imprecision. The sample size is small.

[^5]: ^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane; upper case: MeSH or EMTREE heading; lower case: free text term.

[^6]: Abbreviations: ALT: alanine aminotransferase; GI: gastrointestinal.

[^7]: Abbreviations: ALT: alanine aminotransferase; ELISA: enzyme‐linked immunosorbent assay; IFA: immunofluorescence assay; IgG: immunoglobulin G; IgM: immunoglobulin M; RCT: randomized controlled trial; RDT: rapid diagnostic test.

[^8]: Abbreviations: RCT: randomized controlled trial.

[^9]: Abbreviations: BP: blood pressure; HAART: highly active anti‐retroviral therapy; HIV: human immunodeficiency virus; IgM: immunoglobulin M; LP: lumbar puncture; PCR: polymerase chain reaction; RDT: rapid diagnostic test; SLE: systemic lupus erythematosus; TB: tuberculosis; TNF: tumour necrosis factor.
